Application of Virtual Screening to the Identification of New LpxC Inhibitor Chemotypes, Oxazolidinone and Isoxazoline.
Patrick S LeeGuillaume LapointeAnn Marie MaderaRobert L SimmonsWenjian XuAregahegn YifruMeiliana TjandraSubramanian KarurAlice RicoKatherine ThompsonJade BojkovicLili XieKyoko UeharaAmy LiuWei ShuCornelia BellamacinaDavid McKenneyLaura MorrisGeorge R TonnColin OsborneBret M BentonLaura McDowellJiping FuZachary K SweeneyPublished in: Journal of medicinal chemistry (2018)
This report summarizes the identification and synthesis of novel LpxC inhibitors aided by computational methods that leveraged numerous crystal structures. This effort led to the identification of oxazolidinone and isoxazoline inhibitors with potent in vitro activity against P. aeruginosa and other Gram-negative bacteria. Representative compound 13f demonstrated efficacy against P. aeruginosa in a mouse neutropenic thigh infection model. The antibacterial activity against K. pneumoniae could be potentiated by Gram-positive antibiotics rifampicin (RIF) and vancomycin (VAN) in both in vitro and in vivo models.